

U.K. Haemophilia Centre Director's Hepatitis Working Party

Chairman: Dr. John Craske

Report to Haemophilia Centre Directors at
their Eleventh Meeting, held on 30.9.1980

in Glasgow



Time for previous transfusion - Records regarding samples.

● *Small pool concentrate for mild leucocytes*

infect over known B = B

3,500 Elstree

600 Edin'gh.

10,000 Canad'li C

Cmp > 50 units (vms) - Hepatitis

Table 1

Jaundice in Haemophiliac Patients in the United Kingdom

Year	Treated Patients	No. of Cases	Per Cent
1969	1048	19	1.81
1970	1041	25	2.40
1971	1143	22	1.92
1972	1191	17	1.42
1973	1124	26	2.31
1974	1634	85(101)	5.20 (6.18) Hemofil first used Kryobulin first used
1975	1609	42(51)	2.61(3.17)
1976	1886	56(61)	2.97(3.24) Other Commercial Products
1977	1968	50(54)	2.54(2.74) Koate (Cutter) Factorate (Armour) Profilate (Abbott)
1978	2039	41(47)	2.01(2.30)
1979	1935	33(40)	1.70(2.06)

Date from Biggs, R. (1974)

Biggs and Spooner (1976)

U.K. Haemophilia Survey 1977-9.

Table 2

Hepatitis B and Non-A, Non-B Hepatitis Related to Factor VIII and Transfusions U.K.

Year	Batches Factor VIII	Non-B Hepatitis No. Cases (%)	Hepatitis B (Overt) No. Cases (%)	Total Hepatitis	Total Transfused	Products
1974-5	Q-V(6)	45(14.6%)	26(8.4%)	62*	308F	Hemofil
1975	W-Z4(7)	10(7.4%)	2(1.5%)	12	136F	Hemofil
1975-6	K1-K12	13(10.9%)	4(3.4%)	17	119F	Kryobulin
1977	Not Relevant	33(1.68)	17(0.86)	50(2.54)	1968A	All Products
1978	" "	34(1.66)	8(0.39)	47(2.01)	2039A	" "
1979	" "	29(1.49)	4(0.20)	33(1.7)	1935A	" "
	TOTAL	<u>164</u>	<u>57</u>			

* 9 Patients Suffered 2 Attacks of Hepatitis (Non-B + B). Other Patients had Multiple Attacks of Hepatitis Studied in 1975-6. Data not included in this Survey.

F = Patients first Exposed to Commercial Concentrate

A = All Patients Treated.

Table 3.

Factor VIII/IX Associated Hepatitis - 1977

Patient Diagnosis and Material Received	Cases of Hepatitis			Total Overt Only	Total Patients Transfused
	Non-B Overt Only	B Overt	Symptomless		
Haemophilia 'A'					
NHS Elstree	6(0.66)	4(0.44)	1	10(1.10)	908
Oxford	3(1.67)	0	0	3(1.67)	180
Edinburgh	0	1(0.81)	2	1(0.81)	123
Cryoprecipitate	2(0.15)	1(0.075)	0	3(0.23)	1329
Commercial					
Hemofil	11(2.48)	0	1	11(2.48)	444
Factorate	5(1.58)	7(2.22)	0	12(3.80)	315
Profilate	1(3.7)	0	0	1(3.7)	27
Koate	1(0.41)	1(0.41)	0	2(0.82)	241
Kryobulin	0	1	0	1(0.33)	306
Commercial } Unspecified }	2	2	0	4	Not available
Total	33(1.68)	17(0.86)	4	50(2.54)	1968
Haemophilia 'B'					
NHS IX	4(1.34)	1	0	4*(1.34)	298
Von Willebrands					
Hemofil	1(0.42)	0	0	1(0.42)	237
Secondary Cases	0	1	0	1	
Deaths	None				

One Double Attack of Hepatitis Non-B Followed by Hepatitis B

Two Household Contacts. Patients contracting Non-B Hepatitis also had recently developed Non-B Hepatitis. Both however had recently been transfused with Commercial Non-B Factor VIII concentrate.

Chronic Hepatitis 1
(Jaundice Unknown
Aetiology)

Hepatitis Type }
Unknown - Related } 1
to Blood Products }

Glandular Fever 0

Hepatitis A 0

Total Number of Cases of Overt
Hepatitis Like Illness = 66
(including Symptomless Cases).

Hepatitis not due - Non-B 1
to Blood Products - B 0

Symptomless-Non-B 1

Abnormal LFT's not
related to Hepatitis 1

Table 4

Trends in the Incidence of Factor VIII Associated Hepatitis 1977-79 Haemophilia 'A' Patients

Product	Year	Non-B(%)	Hepatitis B(%)	Total	Total Transfused
NHS					
Elstree	1977	6(0.66)	4(0.44)	10(1.10)	908
	1978	7(0.69)	2(0.19)	9(0.89)	1011
	1979	3(0.30)	0	3(0.30)	973
Cryoprecipitate	1977	2(0.15)	1(0.075)	3(0.28)	1329
	1978	3(0.26)	0	3(0.26)	1120
	1979	2(0.22)	0	2(0.22)	895
Commercial					
Hemofil	1977	11(2.48)	0	11(2.48)	444
	1978	5(1.29)	0	5(1.29)	386
	1979	5(1.34)	0	5(1.34)	373
Factorate	1977	5(1.58)	7 (2.22)	12(3.80)	315
	1978	8(1.33)	4 (1.03)	12(2.00)	599
	1979	10(2.46)	2 (0.30)	12(1.78)	672
Profilate	1977	1(3.7)	0	1(3.70)	27
	1978	2(2.77)	0	2(2.77)	72
	1979	2(2.46)	0	2(2.46)	81
Koate	1977	1(0.41)	1(0.41)	2(0.82)	241
	1978	3(1.17)	0	3(1.17)	255
	1979	2(0.89)	0	0(0.39)	215
Kryobulin	1977	0	1(0.33)	1(0.33)	306
	1978	3(1.71)	0	3(1.71)	175
	1979	2(0.84)	1(0.42)	3(1.26)	237

Table 5

Factor VIII Associated Hepatitis: Commercial and NHS Brands. Attack Rates
on Patients Receiving One Product

Year	Brand	Cases of Hepatitis			Total Overt Hepatitis	Total Transfused	Ratio <u>Commercial</u>	
		Non-B (Overt)	B (Overt)	Symptomless			Non-B	<u>NHS</u> B
1977	Commercial	3(2.67)	2(1.78)	0	5(4.46)	112	4.76	0.79
	NHS	1(0.56)	4(2.23)	0	5(2.79)	179		
1978	Commercial	14(7.7)	1(0.5)	0	15(8.3)	180	19.7	0.79
	NHS	1(0.39)	2(0.63)	0	3(0.96)	313		
1979	Commercial	10(6.32)	1(0.63)	0	11(6.96)	158	21.73	(Not Significant)
	NHS	1(0.29)	0	0	1(0.29)	342		

Table 6
Factor VIII Associated Hepatitis - Relationship
to Age of Patients

Year Treated	Hepatitis Type		Age (Years)						Not known	Total
			<5	6-10	11-20	21-30	31-40	41+		
1974-5	Non-B	No %	0	5 10.4	13 27.0	13 27.0	8 16.6	6 12.5	3 6.2	48
	B	No %	0	8 26.6	8 26.6	3 10.0	5 16.6	4 13.3	2 6.6	30
1977	Non-B	No %	0	5 10.8	14 30.3	7 15.2	7 15.2	16 34.7	0	46
	B	No %	0	2 13.3	2 13.3	3 20.0	3 20.0	5 33.3	0	25
1978	Non-B	No %	1 2.4	2 4.8	1 2.4	10 24.3	6 14.6	12 29.2	9 21.9	41
	B	No %	2 20.0	1 10.0	2 20.0	1 10.0	1 10.0	1 10.0	2 20.0	10
1979	Non-B	No %	1 2.7	3 8.1	2 5.4	8 21.6	6 16.2	16 43.2	3 8.1	37
	B	No %	0	0	1 25	1 225	1 25	1 25	0	4

Table 7

Relationship of Age to Anti-HB_s Status and HB_s Ag Carriers

Group	Severity Coagulation Defect	<5	6-10	11-20	21-30	31-40	40+	Total
Haemophilia A	Severe < 2% VIII	$\frac{3}{7}$ (42.8%) [*]	$\frac{7}{10}$ (70%)	$\frac{32}{36}$ (88.8%) ⁺	$\frac{30}{34}$ (94.1%) [*]	$\frac{17}{17}$ (100)	$\frac{17}{20}$ (85.6%)	$\frac{106}{124}$ (85.4%)
Haemophilia A, vw and Carriers Prior to first Transfusion of Concentrate	Mild > 2%	Nil	Nil	Nil	Nil	$\frac{0}{1}$	$\frac{0}{16}$	$\frac{0}{17}$
Christmas Disease	All Patients	Nil	$\frac{4}{4}$	$\frac{7}{7}$	$\frac{3}{3}$	$\frac{1}{2}$	$\frac{1}{1}$	$\frac{15}{16}$

* $\frac{\text{No. Positive Anti-HB}_s}{\text{Total}}$

+ 3 Patients Carriers of HB_s Ag.

Fig. 1


HBs Ab level in relation to last dose of factor VIII

"AUSAB" RADIOIMMUNOASSAY TEST.

RATIO TOTAL
COUNTS

TEST SERUM
CONTROL SERUM.

HBs Ab level



DAYS SINCE LAST TRANSFUSION OF FACTOR VIII

Ant B
Ant C